ZA200209917B - Piperazinedione compounds. - Google Patents

Piperazinedione compounds. Download PDF

Info

Publication number
ZA200209917B
ZA200209917B ZA200209917A ZA200209917A ZA200209917B ZA 200209917 B ZA200209917 B ZA 200209917B ZA 200209917 A ZA200209917 A ZA 200209917A ZA 200209917 A ZA200209917 A ZA 200209917A ZA 200209917 B ZA200209917 B ZA 200209917B
Authority
ZA
South Africa
Prior art keywords
compound
dione
piperazinedione
methylidene
piperazine
Prior art date
Application number
ZA200209917A
Other languages
English (en)
Inventor
Huei-Ting Chen
Ya-Lan Chen
Yan-Bing Fan
Jih-Hwa Guh
On Lee
Eric I C Li
Che-Ming Teng
Hui-Po Wang
Original Assignee
Adpharma Inc
Teng Che Ming
Wang Hui
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adpharma Inc, Teng Che Ming, Wang Hui filed Critical Adpharma Inc
Publication of ZA200209917B publication Critical patent/ZA200209917B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Saccharide Compounds (AREA)
  • Devices For Conveying Motion By Means Of Endless Flexible Members (AREA)
ZA200209917A 2000-05-09 2002-12-06 Piperazinedione compounds. ZA200209917B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30419100P 2000-05-09 2000-05-09

Publications (1)

Publication Number Publication Date
ZA200209917B true ZA200209917B (en) 2004-04-28

Family

ID=23175471

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200209917A ZA200209917B (en) 2000-05-09 2002-12-06 Piperazinedione compounds.

Country Status (14)

Country Link
US (1) US6635649B2 (enExample)
EP (1) EP1282609B1 (enExample)
JP (1) JP5101781B2 (enExample)
KR (1) KR100852965B1 (enExample)
CN (1) CN100522949C (enExample)
AT (1) ATE417614T1 (enExample)
BR (1) BR0110745A (enExample)
CZ (1) CZ301743B6 (enExample)
DE (1) DE60137037D1 (enExample)
HU (1) HUP0302358A3 (enExample)
NO (1) NO326341B1 (enExample)
RU (1) RU2269520C2 (enExample)
WO (1) WO2001095858A2 (enExample)
ZA (1) ZA200209917B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7288545B2 (en) * 2000-05-09 2007-10-30 Angiorx Corporation Piperazinedione compounds
DK1311269T3 (da) 2000-08-04 2012-03-26 Dmi Biosciences Inc Fremgangsmåde til anvendelse af diketopiperaziner og sammensætning, som indeholder dem
US7919497B2 (en) * 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
US7935704B2 (en) * 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
EP1571970B1 (en) * 2002-10-02 2011-08-17 DMI Biosciences, Inc. Diagnosis and monitoring of diseases
ES2572975T3 (es) 2003-05-15 2016-06-03 Ampio Pharmaceuticals, Inc. Tratamiento de enfermedades mediadas por los linfocitos T
WO2005030083A2 (en) * 2003-09-25 2005-04-07 Dmi Biosciences Inc. Methods and products which utilize n-acyl-l-aspartic acid
CA2553630A1 (en) * 2004-02-04 2005-08-25 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
US8129527B2 (en) * 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
WO2009146320A1 (en) 2008-05-27 2009-12-03 Dmi Life Sciences, Inc. Therapeutic methods and compounds
BRPI0917818A2 (pt) * 2008-08-22 2017-02-21 British Columbia Cancer Agency Branch composto, método para modular a atividade de ar, uso de composto, composição farmacêutica, e, para preparar um composto
CA2757573A1 (en) * 2009-04-16 2010-10-21 Telik, Inc. Substituted 4-amino-5-benzoyl-2-(phenylamino)thiophene-3-carbonitriles and substituted 4-amino-5-benzoyl-2-(phenylamino)thiophene-3-carboxamides as tubulin polymerization inhibitors
US8507496B2 (en) 2010-09-07 2013-08-13 Dmi Acquisition Corp. Treatment of diseases
US8710062B2 (en) * 2011-03-11 2014-04-29 Taipei Medical University Piperazinedione compounds
BR112014007675A2 (pt) 2011-10-10 2017-04-18 Ampio Pharmaceuticals Inc tratamento de doença articular degenerativa
BR112014007657A2 (pt) 2011-10-10 2017-04-11 Ampio Pharmaceuticals Inc dispositivos médicos implantáveis com tolerância imune aperfeiçoada e métodos para produção e implantação
WO2013063413A1 (en) 2011-10-28 2013-05-02 Ampio Pharmaceuticals, Inc. Treatment of rhinitis
US9808454B2 (en) 2013-03-15 2017-11-07 Ampio Pharmaceuticals, Inc. Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
JP6311097B2 (ja) * 2013-07-31 2018-04-18 学校法人東京薬科大学 微小管脱重合剤
EP3183240A4 (en) 2014-08-18 2018-06-27 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
CN104356077B (zh) * 2014-09-11 2016-09-14 中国科学院南海海洋研究所 一类不对称酰基保护的2,5-二酮哌嗪衍生物及其制备方法和应用
SG10202008673WA (en) 2015-03-06 2020-10-29 Beyondspring Pharmaceuticals Inc Method of treating cancer associated with a ras mutation
RU2728796C2 (ru) 2015-03-06 2020-07-31 Бейондспринг Фармасьютикалс, Инк. Способ лечения опухоли головного мозга
HK1246669A1 (zh) 2015-06-22 2018-09-14 Ampio Pharmaceuticals, Inc. 人血清白蛋白低分子量组分在疾病治疗中的应用
CN109516981B (zh) 2015-07-13 2019-10-22 大连万春布林医药有限公司 普那布林组合物
US10912748B2 (en) 2016-02-08 2021-02-09 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
KR20240091084A (ko) 2016-06-06 2024-06-21 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증을 줄이는 조성물 및 방법
JP2020503363A (ja) 2017-01-06 2020-01-30 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド チューブリン結合化合物およびその治療的使用
IL268305B2 (en) 2017-02-01 2024-08-01 Beyondspring Pharmaceuticals Inc Plinabulin in combination with one or more g-csf drug for use in the therapeutic treatment of docetaxel-induced
US11786523B2 (en) 2018-01-24 2023-10-17 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia
CN109580801B (zh) * 2018-06-26 2021-09-07 深圳海王医药科技研究院有限公司 一种检测微管蛋白抑制剂及相关杂质的高效液相色谱法
CN112010930B (zh) * 2019-05-28 2022-08-02 首都医科大学 Rgd修饰的五环哌嗪二酮及其制备和应用
JP2024513505A (ja) 2021-04-09 2024-03-25 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 腫瘍を治療するための組成物及び方法
CN117285516A (zh) * 2022-06-16 2023-12-26 大连万众益生大健康有限公司 脱氢苯基阿夕斯汀类化合物、其制备方法及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5973574A (ja) * 1982-10-21 1984-04-25 Grelan Pharmaceut Co Ltd 環状ジペプチド類
US4806538A (en) * 1984-11-02 1989-02-21 Fujisawa Pharmaceutical Co., Ltd. Piperazine compound as PAF-antagonist
GB8609908D0 (en) * 1986-04-23 1986-05-29 Fujisawa Pharmaceutical Co Piperazine compound
DK181687A (da) * 1986-04-23 1987-10-24 Fujisawa Pharmaceutical Co Piperazinderivater og fremgangsmaade til fremstiling deraf
GB9217331D0 (en) * 1992-08-14 1992-09-30 Xenova Ltd Pharmaceutical compounds
GB9402807D0 (en) * 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
IL112627A0 (en) * 1994-02-14 1995-05-26 Xenova Ltd Diketopiperazines, their preparation and pharmaceutical or veterinary compositions containing them
JP3795093B2 (ja) * 1994-11-25 2006-07-12 キッセイ薬品工業株式会社 １−ヒドロキシインドール誘導体
JP3131574B2 (ja) * 1996-09-04 2001-02-05 新日本製鐵株式会社 新規抗腫瘍物質、該物質を製造するための微生物及び方法、並びに該物質を有効成分とする細胞周期阻害剤及び抗腫瘍剤

Also Published As

Publication number Publication date
CZ301743B6 (cs) 2010-06-09
HUP0302358A2 (hu) 2003-11-28
JP5101781B2 (ja) 2012-12-19
NO20025373L (no) 2002-12-13
BR0110745A (pt) 2003-12-30
HUP0302358A3 (en) 2007-09-28
KR20030005336A (ko) 2003-01-17
CZ20023693A3 (cs) 2003-05-14
CN100522949C (zh) 2009-08-05
NO20025373D0 (no) 2002-11-08
US6635649B2 (en) 2003-10-21
EP1282609A2 (en) 2003-02-12
EP1282609A4 (en) 2003-06-04
NO326341B1 (no) 2008-11-10
WO2001095858A3 (en) 2002-03-21
EP1282609B1 (en) 2008-12-17
RU2269520C2 (ru) 2006-02-10
DE60137037D1 (de) 2009-01-29
CN1441789A (zh) 2003-09-10
ATE417614T1 (de) 2009-01-15
WO2001095858A2 (en) 2001-12-20
KR100852965B1 (ko) 2008-08-19
US20020028819A1 (en) 2002-03-07
JP2004510701A (ja) 2004-04-08

Similar Documents

Publication Publication Date Title
US6635649B2 (en) Piperazinedione compounds
CN103237799B (zh) 杂环衍生物、制备方法及其药学用途
PT1389617E (pt) Composto heterocíclico e agente antitumoral contendo o mesmo como igrediente activo
CA3071900A1 (en) Substituted penta- fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof
AU2005227954B2 (en) Heterocyclic compound and anti-malignant-tumor agent comprising the same as effective component
US8710062B2 (en) Piperazinedione compounds
CA2216265A1 (en) Method for inhibiting the growth of mammalian cells
CN101573337A (zh) 作为抗肿瘤剂的5、6或7-取代-3-(杂)芳基-异喹啉胺衍生物
CA2408649C (en) Piperazinedione compounds
AU2001294505B2 (en) Piperazinedione compounds
US20090163494A1 (en) Protein kinase inhibitors
CN110372627A (zh) 一种1,3,4-噁二唑衍生物及其制备方法和应用
AU2001294505A1 (en) Piperazinedione compounds
AU2020320997B2 (en) Pyridine derivative as FGFR and VEGFR dual inhibitors
AU2018397483A1 (en) Heterocycle compounds as Tyro3, Axl and Mertk (TAM) family of receptor tyrosine kinase inhibitors
EP1270008B1 (en) Fused tricyclic analogues of guanosine for treating tumors
WO2023031246A1 (en) Substituted thiophene compounds as d-dopachrome tautomerase inhibitors
WO2009085040A1 (en) Protein kinase inhibitors
CN108276390A (zh) 一种逆转肿瘤细胞耐药的嘧啶衍生物及其应用